IP Library › Granted Patent US 12,564,651
Granted Patent B2
US 12,564,651 · App. 18/750,073 · Granted Mar 3, 2026

Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging

Inventors: Marcus Kelly (New York, NY); Dangshe Ma (Millwood, NY); William Olson (Yorktown Heights, NY); Gavin Thurston (Briarcliff Manor, NY)
Assignee: REGENERON PHARMACEUTICALS, INC.
A61K51/1045A61K51/0474A61K51/1093C07K16/22C07K16/2827C07K19/00A61K2121/00C07K2317/515C07K2317/565
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,564,651
App. No.
18/750,073
Granted
Mar 3, 2026
Kind
B2
Abstract

Radiolabeled anti-PD-L1 antibodies and their use in immuno-PET imaging are provided herein. Included are methods of detecting the presence of PD-L1 proteins in a patient or sample.

Claims (18)

1 . A compound of Formula (III):

wherein A is an antibody or antigen binding fragment thereof that binds monomeric human program death ligand 1 (PD-L1), wherein:

the antibody or antigen-binding fragment thereof comprises a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence of SEQ ID NO: 84 with no more than one amino acid substitution; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 86 with no more than one amino acid substitution; an HCDR3 comprising the amino acid sequence of SEQ ID NO: 88 with no more than one amino acid substitution; a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence of SEQ ID NO: 92 with no more than one amino acid substitution; an LCDR2 comprising the amino acid sequence of VAS with no more than one amino acid substitution; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 96 with no more than one amino acid substitution;

and k is an integer from 1-30.

2 . The compound of claim 1 , wherein k is 1 or 2.

3 . The compound of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (HCVR) having an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 82.

4 . The compound of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises an HCVR having an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 82.

5 . The compound of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises an HCVR having an amino acid sequence of SEQ ID NO: 82 with no more than 5 amino acid substitutions.

6 . The compound of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises an HCVR having an amino acid sequence of SEQ ID NO: 82 with no more than one amino acid substitution.

7 . The compound of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises an HCVR having an amino acid sequence of SEQ ID NO: 82.

8 . The compound of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a light chain variable region (LCVR) having an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 90.

9 . The compound of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises an LCVR having an amino acid sequence with at least 99% sequence identity to SEQ ID NO: 90.

10 . The compound of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises an LCVR having an amino acid sequence of SEQ ID NO: 90 with no more than 5 amino acid substitutions.

11 . The compound of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises an LCVR having an amino acid sequence of SEQ ID NO: 90 with no more than one amino acid substitution.

12 . The compound of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises an LCVR having an amino acid sequence of SEQ ID NO: 90.

13 . The compound of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises an HCVR having an amino acid sequence of SEQ ID NO: 82 with no more than one amino acid substitution and an LCVR having an amino acid sequence of SEQ ID NO: 90 with no more than one amino acid substitution.

14 . The compound of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises the HCDR1 comprising the amino acid sequence of SEQ ID NO: 84; the HCDR2 comprising the amino acid sequence of SEQ ID NO: 86; the HCDR3 comprising the amino acid sequence of SEQ ID NO: 88; the LCDR1 comprising the amino acid sequence of SEQ ID NO: 92; the LCDR2 comprising the amino acid sequence of VAS; and the LCDR3 comprising the amino acid sequence of SEQ ID NO: 96.

15 . The compound of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises an HCVR having an amino acid sequence of SEQ ID NO: 82 and an LCVR having an amino acid sequence of SEQ ID NO: 90.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2025
From: KELLY, MARCUS; MA, DANGSHE; OLSON, WILLIAM; THURSTON, GAVIN
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 072832/0862 →
Continuity (7)
Continuation 17560003 · Dec 22, 2021
Continuation 16915894 · Jun 29, 2020
Division 15829311 · Dec 1, 2017
Provisional Application 62569773 · Oct 9, 2017
Provisional Application 62457267 · Feb 10, 2017
Provisional Application 62428672 · Dec 1, 2016
Related Publication 20240335572A1 · Oct 10, 2024
References Cited (312)
US 4680338A · Sundoro · 1987 [cited by applicant]
US 5332567A · Goldenberg · 1994 [cited by applicant]
US 5639879A · Mease et al. · 1997 [cited by applicant]
US 6329503B1 · Afar et al. · 2001 [cited by applicant]
US 6814951B1 · Thiele et al. · 2004 [cited by applicant]
US 7387772B1 · Hansen et al. · 2008 [cited by applicant]
US 8545809B2 · D'Souza et al. · 2013 [cited by applicant]
US 8771966B2 · Dennis et al. · 2014 [cited by applicant]
US 9359437B2 · Davis et al. · 2016 [cited by applicant]
US 9429584B2 · Matsumura et al. · 2016 [cited by applicant]
US 9475874B2 · Sawada et al. · 2016 [cited by applicant]
US 9546206B2 · Ring et al. · 2017 [cited by applicant]
US 9562087B2 · Ring et al. · 2017 [cited by applicant]
US 9751945B2 · Ploegh et al. · 2017 [cited by applicant]
US 9938345B2 · Papadopoulos · 2018 [cited by examiner]
US 10081684B2 · Ploegh et al. · 2018 [cited by applicant]
US 10390522B2 · Burova et al. · 2019 [cited by applicant]
US 10730944B2 · Giurleo et al. · 2020 [cited by applicant]
US 10736976B2 · Kelly · 2020 [cited by examiner]
US 10738130B2 · Haber et al. · 2020 [cited by applicant]
US 10905784B2 · Kelly et al. · 2021 [cited by applicant]
US 11117970B2 · Papadopoulos · 2021 [cited by examiner]
US 11511001B2 · Kelly et al. · 2022 [cited by applicant]
US 11525001B2 · Giurleo et al. · 2022 [cited by applicant]
US 11896682B2 · Kelly et al. · 2024 [cited by applicant]
US 12053534B2 · Kelly · 2024 [cited by examiner]
US 12077587B2 · Giurleo et al. · 2024 [cited by applicant]
US 20030077602A1 · Rosen et al. · 2003 [cited by applicant]
US 20030170697A1 · Goldenberg · 2003 [cited by applicant]
US 20040018557A1 · Qu et al. · 2004 [cited by applicant]
US 20040185040A1 · Garcia-Martinez et al. · 2004 [cited by applicant]
US 20040253232A1 · Jakobovits et al. · 2004 [cited by applicant]
US 20050003469A1 · Watkins et al. · 2005 [cited by applicant]
US 20050208043A1 · Adams et al. · 2005 [cited by applicant]
US 20050276812A1 · Ebens et al. · 2005 [cited by applicant]
US 20060177451A1 · Van Den Oudenrijn et al. · 2006 [cited by applicant]
US 20060246005A1 · Yang et al. · 2006 [cited by applicant]
US 20070037148A1 · Fong et al. · 2007 [cited by applicant]
US 20070087005A1 · Gregory et al. · 2007 [cited by applicant]
US 20070122346A1 · Uzgiris et al. · 2007 [cited by applicant]
US 20070160530A1 · Jakobovits et al. · 2007 [cited by applicant]
US 20070280945A1 · Stevens et al. · 2007 [cited by applicant]
US 20080193376A1 · Tawakol et al. · 2008 [cited by applicant]
US 20080260650A1 · Tawakol et al. · 2008 [cited by applicant]
US 20090130108A1 · Reiter · 2009 [cited by applicant]
US 20090203538A1 · Sugioka et al. · 2009 [cited by applicant]
US 20090208489A1 · Veiby et al. · 2009 [cited by applicant]
US 20090208937A1 · Chinnaiyan et al. · 2009 [cited by applicant]
US 20090297439A1 · Comoglio et al. · 2009 [cited by applicant]
US 20100111856A1 · Gill et al. · 2010 [cited by applicant]
US 20100279301A1 · Chinnaiyan et al. · 2010 [cited by applicant]
US 20100285037A1 · Abo et al. · 2010 [cited by applicant]
US 20110076287A1 · Cohen et al. · 2011 [cited by applicant]
US 20110311517A1 · Li et al. · 2011 [cited by applicant]
US 20120058906A1 · Smider et al. · 2012 [cited by applicant]
US 20120195905A1 · Bedian et al. · 2012 [cited by applicant]
US 20120225060A1 · Lee et al. · 2012 [cited by applicant]
US 20130195845A1 · Fendly et al. · 2013 [cited by applicant]
US 20130209481A1 · Zhou et al. · 2013 [cited by applicant]
US 20140112873A1 · Gillies et al. · 2014 [cited by applicant]
US 20140193424A1 · Luo et al. · 2014 [cited by applicant]
US 20140249296A1 · Ploegh et al. · 2014 [cited by applicant]
US 20140322129A1 · Leong et al. · 2014 [cited by applicant]
US 20140377174A1 · Houthoff et al. · 2014 [cited by applicant]
US 20150056209A1 · Witztum et al. · 2015 [cited by applicant]
US 20150191543A1 · Wu et al. · 2015 [cited by applicant]
US 20150203580A1 · Papadopoulos et al. · 2015 [cited by applicant]
US 20150299133A1 · Osterkamp et al. · 2015 [cited by applicant]
US 20160000946A1 · Cheng et al. · 2016 [cited by applicant]
US 20160011217A1 · Matsumura et al. · 2016 [cited by applicant]
US 20160136309A1 · Rosch et al. · 2016 [cited by applicant]
US 20160145350A1 · Longberg et al. · 2016 [cited by applicant]
US 20160151515A1 · Joubert et al. · 2016 [cited by applicant]
US 20160157469A1 · Burova et al. · 2016 [cited by applicant]
US 20170029507A1 · Ho et al. · 2017 [cited by applicant]
US 20170119913A1 · Osterkamp et al. · 2017 [cited by applicant]
US 20170258948A1 · Morin et al. · 2017 [cited by applicant]
US 20170283442A1 · D'Souza et al. · 2017 [cited by applicant]
US 20180015154A1 · Weichert et al. · 2018 [cited by applicant]
US 20180043041A1 · Bansal et al. · 2018 [cited by applicant]
US 20180055947A1 · Van Dongen et al. · 2018 [cited by applicant]
US 20180071413A1 · Olive · 2018 [cited by applicant]
US 20180078662A1 · Agnew et al. · 2018 [cited by applicant]
US 20180126012A1 · Weichert et al. · 2018 [cited by applicant]
US 20180161464A1 · Kelly et al. · 2018 [cited by applicant]
US 20220184241A1 · Kelly et al. · 2022 [cited by applicant]
US 20230270894A1 · Kelly et al. · 2023 [cited by applicant]
US 20240299601A1 · Cheung et al. · 2024 [cited by applicant]
US 20240307563A1 · Kelly et al. · 2024 [cited by applicant]
US 20240409637A1 · Giurleo et al. · 2024 [cited by applicant]
DE 10339820A1 · 2005 [cited by applicant]
DE 102012104504A1 · 2013 [cited by applicant]
EP 1541680A1 · 2005 [cited by applicant]
EP 2196541A1 · 2010 [cited by applicant]
EP 2216344A1 · 2010 [cited by applicant]
EP 2540745A1 · 2013 [cited by applicant]
EP 3266465A1 · 2016 [cited by applicant]
WO 199013256A1 · 1990 [cited by applicant]
WO 199817797A1 · 1998 [cited by applicant]
WO 199839027A2 · 1998 [cited by applicant]
WO 1999055842A1 · 1999 [cited by applicant]
WO 2004016225A2 · 2004 [cited by applicant]
WO 2004101756A2 · 2004 [cited by applicant]
WO 2005068503A2 · 2005 [cited by applicant]
WO 2005113601A2 · 2005 [cited by applicant]
WO 2006034488A2 · 2006 [cited by applicant]
WO 2006053110A2 · 2006 [cited by applicant]
WO 2006099141A2 · 2006 [cited by applicant]
WO 2006121168A1 · 2006 [cited by applicant]
WO 2007005874A2 · 2007 [cited by applicant]
WO 2008052187A2 · 2008 [cited by applicant]
WO 2008067283A2 · 2008 [cited by applicant]
WO 2008124467A1 · 2008 [cited by applicant]
WO 2008141044A2 · 2008 [cited by applicant]
WO 2009005809A2 · 2009 [cited by applicant]
WO 2009033011A1 · 2009 [cited by applicant]
WO 2009045957A1 · 2009 [cited by applicant]
WO 2009068204A1 · 2009 [cited by applicant]
WO 2009073533A2 · 2009 [cited by applicant]
WO 2009120769A1 · 2009 [cited by applicant]
WO 2009129578A1 · 2009 [cited by applicant]
WO 2010016766A2 · 2010 [cited by applicant]
WO 2010111282A1 · 2010 [cited by applicant]
WO 2011021014A2 · 2011 [cited by applicant]
WO 2011051349A1 · 2011 [cited by applicant]
WO 2011056983A1 · 2011 [cited by applicant]
WO 2011153346A1 · 2011 [cited by applicant]
WO 2012045752A1 · 2012 [cited by applicant]
WO 2012087962A2 · 2012 [cited by applicant]
WO 2012098407A1 · 2012 [cited by applicant]
WO 2012177595A1 · 2012 [cited by applicant]
WO 2013010573A1 · 2013 [cited by applicant]
WO 2013025779A1 · 2013 [cited by applicant]
WO 2013028907A1 · 2013 [cited by applicant]
WO 2013061083A2 · 2013 [cited by applicant]
WO 2013063312A1 · 2013 [cited by applicant]
WO 2013070468A1 · 2013 [cited by applicant]
WO 2013071142A1 · 2013 [cited by applicant]
WO 2013138696A1 · 2013 [cited by applicant]
WO 2013149159A1 · 2013 [cited by applicant]
WO 2013165940A1 · 2013 [cited by applicant]
WO 2013169625A1 · 2013 [cited by applicant]
WO 2013173496A2 · 2013 [cited by applicant]
WO 2013177055A2 · 2013 [cited by applicant]
WO 2014151634A1 · 2014 [cited by applicant]
WO 2014153270 · 2014 [cited by applicant]
WO 2014159087A1 · 2014 [cited by applicant]
WO 2014159835A1 · 2014 [cited by applicant]
WO 2014159981A2 · 2014 [cited by applicant]
WO 2014183006A2 · 2014 [cited by applicant]
WO 2014200969A2 · 2014 [cited by applicant]
WO 2014210064 · 2014 [cited by applicant]
WO 2015053871A2 · 2015 [cited by applicant]
WO 2015061209A1 · 2015 [cited by applicant]
WO 2015073746A2 · 2015 [cited by applicant]
WO 2015075445A1 · 2015 [cited by applicant]
WO 2015089344A1 · 2015 [cited by applicant]
WO 2015112805A1 · 2015 [cited by applicant]
WO 2015132602A1 · 2015 [cited by applicant]
WO 2015140212A1 · 2015 [cited by applicant]
WO 2015179658A2 · 2015 [cited by applicant]
WO 2015191715A1 · 2015 [cited by applicant]
WO 2016020502A1 · 2016 [cited by applicant]
WO 2016040723A1 · 2016 [cited by applicant]
WO 2016040724A1 · 2016 [cited by applicant]
WO 2016040868A1 · 2016 [cited by applicant]
WO 2016058056A1 · 2016 [cited by applicant]
WO 2016061142A1 · 2016 [cited by applicant]
WO 2016077518A1 · 2016 [cited by applicant]
WO 2016086021A1 · 2016 [cited by applicant]
WO 2016144873A2 · 2016 [cited by applicant]
WO 2016162368A1 · 2016 [cited by applicant]
WO 2016191186A1 · 2016 [cited by applicant]
WO 2017059397A1 · 2017 [cited by applicant]
WO 2017087826A1 · 2017 [cited by applicant]
WO 2017201111A1 · 2017 [cited by applicant]
WO 2017213494A1 · 2017 [cited by applicant]
WO 2017215590 · 2017 [cited by applicant]
WO 2017223565A1 · 2017 [cited by applicant]
WO 2018049083A1 · 2018 [cited by applicant]
WO 2018058125A1 · 2018 [cited by applicant]
WO 2018083705A1 · 2018 [cited by applicant]
WO 2018128664A2 · 2018 [cited by applicant]
Al-Lazikani et al. (1997) “Standard conformations for the canonical structures of immunoglobulins,” J. Mol. Biol. 273: 927-948. [cited by applicant]
Alley et al. (2010) “Antibody-drug conjugates: targeted drug delivery for cancer”, Current Opinion in Chemical Biology, 14(4): 529-537. [cited by applicant]
Altschul et al. (1990) “Basic Local Alignment Search Tool,” J. Mol. Biol. 215: 403-410. [cited by applicant]
Altschul et al. (1997) “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs”, Nucleic Acids Res. 25(17):3389-3402. [cited by applicant]
Alzimami et al. (2014) “Comparison of Zr-89, I-124, and F-18 Imaging Characteristics in PET Using Gate Monte Carlo Simulations: Imaging,” International Journal of Radiation Oncology, 88: 502. [cited by applicant]
Anonymus (2015) “Human MICL/CLEC12A Antibody, Monoclonal Mouse IgG2B Clone# 687317”, Catalog No. MAB294611, p. 1. [cited by applicant]
Askmyr et al. (2013) “Selective killing of candidate AML stem cells by antibody targeting of IL1RAP,” Blood, 121(18): 3709-3713. [cited by applicant]
Bannerman et al. (2009) “Abstract #5635: The Proteasome Inhibitor MLN9708 Has Strong Anti-Tumor Activity in The Murine Bone Marrow Compartment In Vivo,” Cancer Research, AACR Annual Meeting, 5 pages. [cited by applicant]
Bartel et al. (2009) “F18-Fluorodeoxyglucose Positron Emission Tomography in The Context of Other Imaging Techniques and Prognostic Factors in Multiple Myeloma,” Blood, 114(10): 2068-2076. [cited by applicant]
Beaino et al. (2014) “PET Imaging of Very Late Antigen-4 in Melanoma: Comparison of 68Ga- and 64Cu-Labeled NODAGA and CB-TE1A1P-LLP2A Conjugates,” The Journal of Nuclear Medicine, 55(11): 1857-1862. [cited by applicant]
Boerman and Oyen (2011) “Immuno-PET of Cancer: A Revival of Antibody Imaging,” Journal of Nuclear Medicine, 52(8): 1171-1172. [cited by applicant]
Chang et al. (2015) “Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression,” Cell, 162: 1229-1241. [cited by applicant]
Chatterjee et al. (2016) “A Humanized Antibody for Imaging Immune Checkpoint Ligand PD-L1 Expression in Tumors,” Oncotarget 7(9): 10215-10227. [cited by applicant]
Chattopadhyay et al. (2009) “Sequence, Structure, Function, Immunity: Structural Genomics of Costimulation,” Immunol. Rev. 229(1): 356-386. [cited by applicant]
Chen et al. (2013) “Molecular Mechanisms of T cell co-stimulation and co-inhibition,” Nature Rev. Immunol. 13(4): 227-242. [cited by applicant]
De Lau et al. (2011) “Lgr5 Homologues Associate with Wnt Receptors and Mediate R-spondin Signalling,” Nature, 476(7360): 293-297. [cited by applicant]
De Vries “Antibody immunotherapy Imaging,” Department of Medical Oncology University Medical Center Groningen, The Netherlands, 16 pages. [cited by applicant]
De Vries (2015) “MPDL3280A-imaging-IST-UMCG,” ClinicalTrials.gov Identifier: NCT02453984, University Medical Center Groningen, 10 pages. [cited by applicant]
Deng et al. (2016) “Preclinical Pharmacokinetics, Pharmacodynamics, Tissue Distribution, and Tumor Penetration of Anti-PD-L1 Monoclonal Antibody, an Immune Checkpoint Inhibitor,” mAbs, 8(3): 593-603. [cited by applicant]
Deri et al. (2015) “p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPET,” Bioconjugate Chem., 26(12): 2579-2591. [cited by applicant]
Dijkers et al. (2019) “Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients with Metastatic Breast Cancer,” Clinical Pharmacology and Therapeutics, 87(5): 586-592. [cited by applicant]
Dijkers et al. (2009) “Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging,” Journal of Nuclear Medicine, 50(6): 974-981. [cited by applicant]
Dong et al. (1999) “B7-H1, a Third Member of the B7 family, Co-stimulates T-cell Proliferation and Interleukin-10 Secretion,” Nature Medicine, 5(12): 1365-1369. [cited by applicant]
Feng et al. (2013) “Glypican-3 Antibodies: A New Therapeutic Target for Liver Cancer,” FEBS Letters, 588(2): 377-382. [cited by applicant]
Feng et al. (2013) “Therapeutically Targeting Glypican-3 Via a Conformation-specific Single-domain Antibody in Hepatocellular Carcinoma,” Proceedings of The National Academy Of Sciences, 110(12): E1083-E1091. [cited by applicant]
Feng et al. (2009) “A Novel Human Monoclonal Antibody that Binds with High Affinity to Mesothelin-expressing Cells and Kills Them by Antibody-dependent Cell-mediated Cytotoxicity,” Molecular Cancer Therapeutics, America… [cited by applicant]
Fischer et al. (2013) “89Zr, a Radiometal Nuclide with High Potential for Molecular Imaging with PET: Chemistry, Applications and Remaining Challenges,” Molecules, 18: 6469-6490. [cited by applicant]
Fisher et al. (2002) “Generation of Monocolonal Antibodies Specific for Human Kallikrein 2 (hK2) Using hK2-Expresing Tumors,” The Prostate, 51: 153-165. [cited by applicant]
Francisco et al. (2010) “The PD-1 Pathway in Tolerance and Autoimmunity,” Immunol Rev., 236: 219-242. [cited by applicant]
Freeman (2008) “Structures of PD-1 with Its Ligands: Sideways and Dancing Cheek to Cheek,” PNAS, 105(30): 10275-10276. [cited by applicant]
Gao et al. (2014) “Lgr5 Over-Expression is Positively Related to the Tumor Progression and HER2 Expression in Stage pTNM IV Colorectal Cancer,” Int. J. Clin. Exp. Pathol., 7(4): 1572-1579. [cited by applicant]
Garcia-Teijido et al. (2016) “Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting,” Clin Med Insights Oncol, 10(S1): 31-39. [cited by applicant]
Gebhart et al. (2015) “Molecular Imaging as a Tool to Investigate Heterogeneity of Advanced HER2-positive Breast Cancer and to Predict Patient Outcome Under Trastuzumab Emtansine (T-DM1); the ZEPHIR Trial,” Annals of On… [cited by applicant]
GenBank Accession No. ACV51637.1 TO: Protein [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; [2013]—Accession No. ACV51637.1, “Hypothetical Protein Apar_1209 … [cited by applicant]
GenBank Accession No. CAJ48864.1 TO: Protein [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; [2015]—Accession No. CAJ48864.1, “Putative Membrane Protein [Bord… [cited by applicant]
GenBank Accession No. NP_005009.2 TO: Protein [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; [2019]—Accession No. NP_005009.2, “Programmed Cell Death Protein… [cited by applicant]
GenBank Accession No. NP_005182.1 TO: Protein [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; [2018]—Accession No. NP_005182.1, “T-lymphocyte Activation Antig… [cited by applicant]
Glunde et al. (2011) “Magnetic Resonance Spectroscopy and Imaging Guidance in Molecular Medicine: Targeting and Monitoring of Choline and Glucose Metabolism In Cancer,” NMR in Biomedicine, 24(6): 673-690. [cited by applicant]
Gonnet et al. (1992) “Exhaustive Matching of the Entire Protein Sequence Database,” Science 256: 1443-1445. [cited by applicant]
Govindan et al. (2005) “Deferoxamine as A Chelator For [cited by applicant]
Gupta et al. (2010) “Clinical Pharmacokinetics of Intravenous and Oral MLN9708, An Investigational Proteasome Inhibitor: An Analysis of Data from Four Phase 1 Monotherapy Studies,” Blood, 116: 1813. [cited by applicant]
Hanaoka et al. (2015) “Glypican-3 Targeted Human Heavy Chain Antibody as a Drug Carrier for Hepatocellular Carcinoma Therapy,” Molecular Pharmaceutics, 12(6): 2151-2157. [cited by applicant]
Hassan et al. (2007) “Preclinical Evaluation of MORAb-009, a Chimeric Antibody Targeting Tumor-associated Mesothelin,” Cancer Immunity, Academy of Cancer Immunology, 7: 20. [cited by applicant]
Herbst et al. (2014) “Predictive Correlates of Response to the Anti-PD-L1 Antibody MPDL3280A in Cancer Patients,” Nature 515(7528): 563-567. [cited by applicant]
Heskamp et al. (2015) “Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies,” Cancer Res, 75(14): 2928-2936. [cited by applicant]
Higashikawa et al. (2014) “64Cu-DOTA-Anti-CTLA-4 mAb Enabled PET Visualization of CTLA-4 on the T-Cell Infiltrating Tumor Tissues,” PLoS One, 9(11): e109866, 8 pages. [cited by applicant]
Holland et al. (2009) “Standardized Methods for the Production of High Specific-Activity Zirconium-89,” Nucl. Biol., 36(7): 729-739. [cited by applicant]
Huang et al. (2010) “Biodistribution, Toxicity and Radiation Dosimetry Studies of the Serotonin Transporter Radioligand 4-[18F]-ADAM in Rats and Monkeys,” Eur J Nucl Med Mol Imaging, 37(3): 545-555. [cited by applicant]
International Commission on Radiological Protection. 1990 Recommendations of the International Commission on Radiological Protection. ICRP Publication 60, Pergamon Press, New York, 1991, 1 page Abstract. [cited by applicant]
International Search Report and Written Opinion received in PCT/US2017/064215, on Feb. 9, 2018, 16 pages. [cited by applicant]
Iyer et al. (2011) “Antibody Drug Conjugates—Trojan Horses in the War on Cancer,” Journal of Pharmacological and Toxicological Methods, 64(3): 207-212. [cited by applicant]
Järås et al. (2010) “Isolation and Killing of Candidate Chronic Myeloid Leukemia Stem Cells by Antibody Targeting of IL-1 receptor Accessory Protein,” Proceedings of the National Academy of Sciences, National Academy of… [cited by applicant]
Jauw et al. (2016) “Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?”, Frontiers in Pharmacology, vol. 7, Article 131, 15 p… [cited by applicant]
Josefsson et al. (2016) “Imaging Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer,” Cancer Research, 76(2): 472-479. [cited by applicant]
Junutula et al. (2008) “Rapid Identification of Reactive Cysteine Residues for Site-specific Labeling of Antibody-Fabs”, Journal of Immunological Methods, 332(1-2): 41-52. [cited by applicant]
Junutula et al. (2008) “Site-specific Conjugation of a Cytotoxic Drug to an Antibody Improves the Therapeutic Index,” Nature Biotechnology, 26(8): 925-932. [cited by applicant]
Kabat (1991) “Sequences of Proteins of Immunological Interest,” National Institutes of Health, Bethesda, Md., 147:1709-1719. [cited by applicant]
Keliher et al. (2011) “89Zr-labeled Dextran Nanoparticles Allow In Vivo Macrophage Imaging,” Bioconjugate Chemistry, 22(12): 2383-2389. [cited by applicant]
Kelly et al. (2017) “Immuno-PET Using Zirconium-89 (89Zr) Radiolabeled Fully Human Anti-PD-L1 Antibody Successfully Images PD-L1 Positive Tumors in Preclinical Mouse Models,” Journal of Nuclear Medicine 58(S1): 618. [cited by applicant]
Lamberts et al. (2015) “ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer Before Anti-Mesothelin Antibody-Drug Conjugate Treatment,” Clinical Cancer Research, 22(7): 1642-1652. [cited by applicant]
Lasorsa et al. (2016) “Probing the Interaction Between Cisplatin and the Therapeutic Monoclonal Antibody Trastuzumab,” RSC Advances, 6(35): 29229-29236. [cited by applicant]
Le Beau et al. (2013), “Targeting uPAR with Antagonistic Recombinant Human Antibodies in Aggressive Breast Cancer,” Cancer Res, 73(7): 2070-2081. [cited by applicant]
Leong et al. (2015) “An Anti-B7-H4 Antibody-Drug Conjugate for the Treatment of Breast Cancer,” Molecular Pharmaceutics, 12(6): 1717-1729. [cited by applicant]
Lesniak et al. (2016) “PD-L1 Detection in Tumors Using [64 Cu]Atezolizumab with PET,” Bioconjugate Chemistry, 27(9): 2103-2110. [cited by applicant]
Li and Zhu (2016) “Immuno-PET Imagining Using 89Zr Labeled PD-L1 antibody in Non-small Cell Lung Cancer Xenograft,” J. Nucl. Med., 57(S2): 337. [cited by applicant]
Li et al. (2012) “MLN9708 Shows Encouraging Results for The Treatment Of Multiple Myeloma (ASCO 2012),” The Myeloma Beacon, 3pages. [cited by applicant]
Li et al. (2014) “Addition of Bevacizumab Enhances Antitumor Activity of Erlotinib Against Non-small Cell Lung Cancer Xenografts Depending on VEGF Expression,” Cancer Chemother Pharmacol., 74(6): 1297-305; Abstract. [cited by applicant]
Lloyd (1999) The Art, Science and Technology of Pharmaceutical Compounding, 8pgs. [cited by applicant]
Lu et al. (2009) “Abstract#1233: Development of Anti-glypican 3 Therapeutic Antibodies,” AACR Annual Meeting, 50: 296. [cited by applicant]
Martin et al. (1989) “Modeling Antibody Hypervariable Loops: A Combined Algorithm,” Proc. Natl. Acad. Sci. USA 86: 9268-9272. [cited by applicant]
Maute et al. (2015) “Engineering High-affinity PD-1 Variants for Optimized Immunotherapy and Immuno-PET Imaging,” Proc Natl Acad Sci U S A, 112(47): E6506-E6514. [cited by applicant]
Meijs et al. (1997) “Zirconium-labeled Monoclonal Antibodies and their Distribution in Tumor-bearing Nude Mice,” J Nucl Med, 38(1): 112-118. [cited by applicant]
Mindt et al. (2014) “Octadetante Bifunctional Chelating Agent for Zr-89 Based Imagining Probes,” Technology Opportunity, Ref. No. UZ-15/736, 1 page. [cited by applicant]
Morita et al. (2004) “Neonatal Lethality of LGR5 Null Mice is Associated with Ankyloglossia and Gastrointestinal Distension,” Mol Cell Biol., 24(22): 9736-9743. [cited by applicant]
Nakano et al. (2010) “Generation of a Humanized Anti-glypican 3 Antibody by CDR Grafting and Stability Optimization,” Anti-Cancer Drugs, 21(10): 907-916. [cited by applicant]
Nakano et al. (2009) “Anti-glypican 3 Antibodies Cause ADCC Against Human Hepatocellular Carcinoma Cells,” BBRC, 378(2): 279-284. [cited by applicant]
Natarajan et al. (2015) “Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes”, Bioconjug Chem, 26(10):2062-2069. [cited by applicant]
Nijland et al. (2019) “Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients,” University Medical Center Groningen, ClinicalTrials.gov Identifier: NCT03850028, 11 … [cited by applicant]
Onda et al. (2005) “New Monoclonal Antibodies to Mesothelin Useful for Immunohistochemistry, Fluorescence-activated Cell Sorting, Western Blotting, and ELISA,” Clin Cancer Res, 11(16): 5840-5846. [cited by applicant]
Onda et al. (2006) “Megakaryocyte Potentiation Factor Cleaved from Mesothelin Precursor Is a Useful Tumor Marker in the Serum of Patients with Mesothelioma”, Clin Cancer Res, 12(14 Pt 1):4225-4231. [cited by applicant]
Oosting et al. (2015) “89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment,” The Journal of Nuclear Me… [cited by applicant]
Padldan et al. (1995) “Identification of Specificity-determining Residues in Antibodies,”, FASEB J. 9: 133-139. [cited by applicant]
Pandya et al. (2015) “Di-macrocyclic Terephthalamide Ligands as Chelators for the PET Radionuclide Zirconium-89”, Chem Commun (Camb), 51(12): 2301-2303. [cited by applicant]
Pantin et al. (2012) “Optimization of an Intra-Bone Hematopoietic Stem Cell Delivery Technique in a Swine Model (Abstract 2990),” Blood, 120(21): 2990. [cited by applicant]
Pearson (1994) “Using the FASTA Program to Search Protein and DNA Sequence Databases,” Methods Mol. Biol. 24: 307-331. [cited by applicant]
Perk et al. (2010) “p-Isothiocyanatobenzyl-desferrioxamine: A New Bifunctional Chelate for Facile Radiolabeling of Monoclonal Antibodies with Zirconium-89 for Immuno-PET Imaging,” Eur. J. Nucl. Med. Mol Imaging, 37(2): … [cited by applicant]
Petrick et al. (2015) “In Vitro and In Vivo Comparison of Selected Ga-68 and Zr-89 Labelled Siderophores,” Mol. Imaging Biol., 18: 344-352. [cited by applicant]
Phung et al., (2012) “High-affinity Monoclonal Antibodies to Cell Surface Tumor Antigen Glypican-3 Generated Through a Combination of Peptide Immunization and Flow Cytometry Screening,” MAbs, 4(5): 592-599. [cited by applicant]
Price et al. (2014) “Hophospa-trastuzumab: Bifunctional Methylenephosphonate-based Chelator with 89Zr, 111In and 177Lu,” Dalton Trans., 43(1): 119-131. [cited by applicant]
Pritsch et al. (1993) “V Gene Usage by Seven Hybrids Derived from CD5+ B-Cell Chronic Lymphocytic Leukemia and Displaying Autoantibody Activity,” Blood, 82(10): 3103-3112. [cited by applicant]
Ribas (2012) “Tumor Immunotherapy Directed at PD-1,” N. Engl. J. Med., 366(26): 2517-2519. [cited by applicant]
Ricart et al. (2007) “Technology Insight: Cytotoxic Drug Immunoconjugates for Cancer Therapy,” Nature Clinical Practice Oncology, 4(4): 245-255. [cited by applicant]
Rojko et al. (2014) “Formation, Clearance, Deposition, Pathogenicity, and Identification of Biopharmaceutical-related Immune Complexes: Review and Case Studies,” Toxicol Pathol. 42(4) :725-764. [cited by applicant]
Sasaki et al. (2010) “Establishment of a Novel Monoclonal Antibody Against LGR5,” BBRC, 394(3): 498-502. [cited by applicant]
Schumacher et al. (2016) “Current Status: Site-Specific Antibody Drug Conjugates,” J Clin Immunol., 36(1): S100-S107. [cited by applicant]
Sheridan (2012) “Cautious Optimism Surrounds Early Clinical Data for PD-1 Blocker,” Nature Biotechnology 30(8): 729-730. [cited by applicant]
Slizys and Widnersson (2016) “The New “Pet” on the Block: Radio Imaging with Zirconium-89,” FPA Patent Attorneys, 5 pages. [cited by applicant]
Smith et al. (2010) “Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 are Localized Primarily to the Vasculature in Human Primary Solid Cancers,” Clin Cancer Res., 16(14): 3548-3561. [cited by applicant]
Souza et al. (2005) “Peripheral B Cells Latently Infected with Epstein-Barr Virus Display Molecular Hallmarks of Classical Antigen-Selected Memory B Cells,” Proc Natl Acad Sci USA, 102(50): 18093-18098. [cited by applicant]
Sugyo et al. (2013) “Evaluation of 89Zr-Labeled Human Anti-CD147 Monoclonal Antibody as a Positron Emission Tomography Probe in a Mouse Model of Pancreatic Cancer,” PLOS ONE, 8(4): e61230, 9 pages. [cited by applicant]
Takahashi et al. (2010) “Significance of Lgr5Cancer Stem Cells in the Colon and Rectum,” Annals of Surgical Oncology, 18(4): 1166-1174. [cited by applicant]
Tavare et al. (2016) “An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy,” Cancer Research, 76(1): 73-82. [cited by applicant]
Terrovitis et al. (2010) “Assessment and Optimization of Cell Engraftment After Transplantation into the Heart”, Circ Res., 106(3):479-494. [cited by applicant]
Tinianow et al. (2010) “Site-specifically 89Zr-labeled Monoclonal Antibodies for ImmunoPET,” Nucl Med Biol., 37(3): 289-297. [cited by applicant]
Vajdos et al. (2002) “Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis,” J Mol Biol., 320: 415-428. [cited by applicant]
Valenzuela et al. (2003) “High-throughput Engineering of the Mouse Genome Coupled with High-resolution Expression Analysis,” Nat. Biotechnol., 21: 652-659. [cited by applicant]
Van De Watering et al. (2014) “Zirconium-89 Labeled Antibodies: A New Tool for Molecular Imaging in Cancer Patients”, Biomed Research international, Article ID 203601, 2014:1-13. [cited by applicant]
Van Dongen et al. (2007) “Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications,” The Oncologist, 12: 1379-1389. [cited by applicant]
Vansteenkiste et al. (1999) “Prognostic Importance of the Standardized Uptake Value on 18F-Fluoro-2-Deoxy-Glucose-Positron Emission Tomography Scan In Non-Small-Cell Lung Cancer: An Analysis of 125 Cases”, J Clin Oncol.… [cited by applicant]
Verel et al. (2003) “89Zr Immuno-PET: Comprehensive Procedures for the Production of 89Zr-labeled Monoclonal Antibodies,” J Nucl Med., 44(8): 1271-1281. [cited by applicant]
Vosjan et al. (2010) “Conjugation and Radiolabeling of Monoclonal Antibodies with Zirconium-89 for PET Imaging Using the Bifunctional Chelate p-isothiocyanatobenzyl-desferrioxamine,” Nature Protocols, 5(4): 739-743. [cited by applicant]
Vugts et al. (2017) “Comparison of the Octadentate Bifunctional Chelator DFO*-pPhe-NCS and the Clinically Used Hexadentate Bifunctional Chelator DFO-pPhe-NCS for 89Zr-immuno-PET,” European Journal of Nuclear Medicine an… [cited by applicant]
Waalboer et al. (2015) “Platinum (II) as Bifunctional Linker in Antibody-Drug Conjugate Formation: Coupling of a 4-Nitrobenzo-2-oxa-1,3-diazole Fluorophore to Trastuzumab as a Model,” ChemMedChem, 10(5): 797-803. [cited by applicant]
Walker et al. (2011) “LGR5 Is a Negative Regulator of Tumourigenicity, Antagonizes Wnt Signalling and Regulates Cell Adhesion in Colorectal Cancer Cell Lines,” PLoS One, 6(7): e22733.1-20. [cited by applicant]
Ward et al. (2013) “HDAC Inhibition Induces Increased Choline Uptake and Elevated Phosphocholine Levels in MCF7 Breast Cancer Cells,” PLoS One, 8(4): e62610.1-11. [cited by applicant]
Wu et al. (2012) “Lgr5 Is a Potential Marker of Colorectal Carcinoma Stem Cells that Correlates with Patient Survival,” World J Surg Oncol., 10(1): 244. [cited by applicant]
Yamauchi et al. (2005) “The Glypican 3 Oncofetal Protein is a Promising Diagnostic Marker for Hepatocellular Carcinoma,” Modern Pathology, 18(12): 1591-1598. [cited by applicant]
Yang et al. (2014) “Imaging of Hepatocellular Carcinoma Patient-derived Xenografts Using 89Zr-labeled Anti-glypican-3 Monoclonal Antibody,” Biomaterials, 35(25): 6964-6971. [cited by applicant]
Yasumoto et al. (2004) “Epitope Mapping of the Melanosomal Matrix Protein gp100 (PMEL17) rapid processing in the endoplasmic reticulum and glycosylation in the early Golgi compartment,” J Biol Chem., 279(27): 28330-2833… [cited by applicant]
Yoon et al. (1998) “Antibodies to Domains II and III of the IL-1 Receptor Accessory Protein Inhibit IL-1 Beta Activity but Not Binding: Regulation of IL-1 Responses is Via Type I Receptor, Not the Accessory Protein,” J … [cited by applicant]
Zhai et al. (2015) “Novel Bifunctional Cyclic Chelator for (89)Zr Labeling-Radiolabeling and Targeting Properties of RGD Conjugates,” Mol. Pharmaceutics, 12: 2142-2150. [cited by applicant]
Zhu et al. (2013) “First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma,” Clin Cancer Res., 19(4): 920-928. [cited by applicant]
Jing et al. (2015) “Combined Immune Checkpoint Protein Blockade and Low Dose Whole Body Irradiation as Immunotherapy for Myeloma”, J. for Immuno. Therapy of Cancer, 3(2): 1-15. [cited by applicant]
Patra et al. (2014) “An Octadentate Bifunctional Chelating Agent for the Development of Stable Zirconium-89 Based Molecular Imaging Probes”, Chem. Commun., 50: 11523-11525. [cited by applicant]
Knight et al. (2016) “Scaling-down Antibody Radiolabeling Reactions With Zirconium-89”, Dalton Trans., 45: 6343-6347. [cited by applicant]
Mottaghy et al. (2016) “Molecular Imaging Using PSMA PET/CT Versus Multiparametric MRI for Initial Staging of Prostate Cancer: Comparing Apples with Oranges?” Eur. J. Nucl. Med. Mol. Imaging, 43: 1397-1399. [cited by applicant]
NCT03780725 on Dec. 19, 2018, ClinicalTrials.gov Archive, “This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI… [cited by applicant]
Perk et al. (2008) “Facile Radiolabeling of Monoclonal Antibodies and Other Proteins with Zirconium-89 or Gallium-68 for PET Imaging Using P-isothiocyanatoenzyl-desferrioxamine,” Protocol Exchange, XP055750961. [cited by applicant]
Perk et al. (2008) “Quantitative PET Imaging of Met-expressing Human Cancer Xenografts with 89Zr-labelled Monoclonal Antibody DN30,” European Journal of Nuclear Medicine and Molecular Imaging, 35(10): 1857-1867. [cited by applicant]
Cited By (1)
US 12,721,914